ZURICH, May 20 (Reuters) - Idorsia has raised 330 million Swiss francs ($340.31 million) from a share offering, the Swiss drugmaker said on Wednesday, as it bolsters its coffers for the planned launch of an insomnia drug and for research and development.
Idorsia placed 11 million new registered shares of 0.05 francs par value each at 30 francs per new share. The shares, which amount to 8.4% of Idorsia’s currently issued share capital, will likely begin trading Friday, it said.
Barclays Bank and Credit Suisse acted as joint bookrunners for the offering. Octavian acted as a selling agent. ($1 = 0.9697 Swiss francs) (Reporting by John Miller, editing by John Revill)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.